PATENT CLAIM ANALYSIS

Application Number: 16016250
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "279000"]

Abstract:
The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.

Claim (Index 18):
The method of  claim 4 , wherein the method of treating opioid use disorder is a method for eliminating illicit opioid use.

Metadata:
- Claim Count in Document: 110.0
- Percentile: 94.0
- Lexical Diversity: 1.04762
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15623191', '13836134', '15857507', '14610818', '15334000']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.80439435199257
- 35 USC 102 Novelty (BERT): 0.5301052670394106
- Combined Prediction Score: 0.776965443497254
- Mean Citation Score: 302.2236400000001
- Max Citation Score: 315.9235
- Similarity Product: 183.42172663795947

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test